Because LeukoScan has not been studied in patients aged 21 years or younger, doctors should carefully weigh the benefits and the risks of its use before administering it to a patient in this age group.
Da LeukoScan ikke er blevet undersøgt hos patienter i alderen 21 år eller derunder, bør lægen omhyggeligt afveje fordele og risici ved brugen af LeukoScan, inden behandlingen gives til en patient i denne aldersgruppe.